Walleye Capital LLC Edgewise Therapeutics, Inc. Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$11.42 - $20.13 $807,439 - $1.42 Million	70,704 Added 437.04%	86,882 $1.14 Million
Q1 2025 May 14, 2025	SELL	$22.0 - $30.03 $4.01 Million - $5.48 Million	-182,484 Reduced 91.86%	16,178 $355,000
Q4 2024 Feb 13, 2025	SELL	$26.63 - $36.62 $1.16 Million - $1.6 Million	-43,589 Reduced 17.99%	198,662 $5.3 Million
Q3 2024 Nov 14, 2024	BUY	$15.88 - $29.5 $3.85 Million - $7.15 Million	242,251 New	242,251 $6.47 Million
Q2 2022 Aug 08, 2022	SELL	$5.67 - $9.87 $46,471 - $80,894	-8,196 Reduced 32.53%	17,000 $135,000

Q1 2022 May 16, 2022	BUY	$9.1 - $18.97 $229,283 - $477,968	25,196 New	25,196 $244,000

186

112M

188K

121K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.44B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.